Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-10-20 00:00:00 ET · period of report 2022-10-18 · accession 0000899243-22-033880 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-10-20 | 2022-10-18 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.31 | -1,791 | 39.5K | -4% | -$537.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-18 | S | D | 288 | $301.84 | 39,192 | D | — | — | (F2) Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $301.84 (range $301.14 to $301.98). |
| 2 | Common | Common Stock | 2022-10-18 | S | D | 1,503 | $300.02 | 39,480 | D | — | — | (F2) Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $300.02 (range $300.00 to $300.14). |